Business
Notice of Investor Meet Company Presentation
Notice of Investor Meet Company Presentation.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n\n\n \nSkinBioTherapeutics plc\n(\"SkinBioTherapeutics\" or \"the Company\")\n \nNotice of Investor Meet Company presentation\n\n4 October 2024 - SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, will be giving an update to investors on Friday 11 October 2024 via the Investor Meet Company platform.\nThe presentation will take place at 10am (BST) via this link HERE. Questions can be submitted pre-event via the Investor Meet Company dashboard up to the day before the meeting or at any time during the presentation.\nInvestors who already follow SkinBioTherapeutics on the Investor Meet Company platform will automatically be invited. Investors can sign up to Investor Meet Company for free via this link.\n \nFor more information please contact:\n \n\n\n\n\nSkinBioTherapeutics plc\nStuart J. Ashman, CEO\nManprit Randhawa, CFO\n \n\n\n+44 (0) 191 495 7325\n \n\n\n\n\nCavendish Capital Markets Limited\n(Nominated Adviser & Broker)\nGiles Balleny, Dan Hodkinson (Corporate Finance)\nCharlie Combe (Broking)\nDale Bellis, Tamar Cranford-Smith (Sales)\n \n\n\n+44 (0) 20 7220 0500\n \n\n\n\n\nVigo Consulting (financial press)\nRozi Morris\n \n\n\n+44 (0) 20 7390 0230\[email protected]\n \n\n\n\n\nNotes to Editors\nAbout SkinBioTherapeutics plc\nSkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.\nThe Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.\nThe Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.\n \n\n","length":6308,"tagName":"div"}]